Opendata, web and dolomites

FOLSMART SIGNED

Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FOLSMART project word cloud

Explore the words cloud of the FOLSMART project. It provides you a very rough idea of what is the project "FOLSMART" about.

folate    drugs    neck    technological    rat    validate    mtx    nanofol    tolerability    good    hsa    scores    efficacy    elaborated    carcinogenicity    poses    nanoparticles    sensitive    fp7    economic    manufacturing    bench    claims    activated    models    domain    sulfasalazine    glp    laboratory    marketed    first    business    acid    agent    drug    health    liposomal    ph    indication    therapy    optimization    macrophages    tolerance    encapsulating    performed    dog    model    plans    public    biological    hospital    showed    intolerant    methotrexate    ssz    release    patients    arthritis    benefit    temperature    burden    pharmacokinetics    genotoxicity    mouse    ra    trials    treatment    conjugates    fa    treatments    nanodevices    mechanisms    benchmarked    tested    mediated    toxicity    positively    initial    gmp    folsmart    folic    alternatives    line    peptide    therapies    toxicology    animal    rheumatoid    unresponsive    clinical    fbn    marked    evaluation    parallel    standards   

Project "FOLSMART" data sheet

The following table provides information about the project.

Coordinator
ASSOCIACAO UNIVERSIDADE EMPRESA PARA DESENVOLVIMENTO TECMINHO 

Organization address
address: CAMPUS DE AZUREM UNIVERSIDADE DO MINHO
city: GUIMARAES
postcode: 4800 058
website: www.tecminho.uminho.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.folsmart.net
 Total cost 4˙993˙833 €
 EC max contribution 4˙993˙833 € (100%)
 Programme 1. H2020-EU.2.1.2.2. (Ensuring the safe and sustainable development and application of nanotechnologies)
2. H2020-EU.2.1.2.5. (Developing and standardisation of capacity-enhancing techniques, measuring methods and equipment)
3. H2020-EU.2.1.2.3. (Developing the societal dimension of nanotechnology)
 Code Call H2020-NMP-PILOTS-2015
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSOCIACAO UNIVERSIDADE EMPRESA PARA DESENVOLVIMENTO TECMINHO PT (GUIMARAES) coordinator 1˙142˙037.00
2    BLUECLINICAL - INVESTIGACAO E DESENVOLVIMENTO EM SAUDE LDA PT (MOTOSINHOS) participant 629˙845.00
3    APTUIT (VERONA) SRL IT (VERONA) participant 544˙440.00
4    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 488˙400.00
5    INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC PT (PORTO) participant 436˙823.00
6    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 404˙510.00
7    UNIVERSITAET FUER BODENKULTUR WIEN AT (WIEN) participant 399˙556.00
8    BLUEPHARMA - INDUSTRIA FARMACEUTICASA PT (COIMBRA) participant 327˙671.00
9    SOLFARCOS - SOLUÇÕES FARMACÊUTICAS E COSMÉTICAS LDA PT (BRAGA) participant 311˙675.00
10    SYNOVO GMBH DE (TUEBINGEN) participant 300˙000.00
11    GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG DE (MUENCHEN) participant 8˙875.00

Map

 Project objective

FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved clinical scores in a mouse model of RA when compared to methotrexate (MTX), a first-line drug therapy for the treatment of RA. In this way, FBN will be benchmarked against this drug. MTX has significant associated toxicity and second line biological therapies poses a great economic burden to hospital/public health systems. In parallel, nanodevices encapsulating Sulfasalazine (SSZ), will be tested. SSZ is a second line indication for the treatment of RA, unresponsive to MTX or MTX–intolerant patients. Furthermore, FOLSMART propose the optimization of mechanisms for the release of the drugs, through pH and temperature sensitive nanodevices. An exploitation and business plans will be elaborated. In parallel, initial economic evaluation of all proposed treatments will be performed to validate these claims.

Specific technological objectives of FOLSMART will be:

Good Manufacturing Practice (GMP) production of the FBN based therapies which have been positively bench-marked in the previous FP7 European project NANOFOL in comparison with the use of MTX in a RA mouse model: -Liposomal MTX and SSZ with FA-“neck domain” peptide as targeting agent -Nanoparticles from HSA-FA/MTX conjugates and SSZ -Optimization of mechanisms of drug release and application to other fields

Pre-clinical development on RA models -Toxicology and pharmacokinetics, to determine tolerability and efficacy benefit in two animal models rat and dog, under Good Laboratory Practice (GLP) standards -Genotoxicity and Carcinogenicity

Phase I clinical trials of the best therapies bench marketed against MTX -Nanodevices with MTX and SSZ will offer improved tolerance and greater efficacy meaning that patients who do not do well on MTX will have cost-effective alternatives

 Deliverables

List of deliverables.
Exploitation activity - yearly report 2 in knowledge subjected of protection Documents, reports 2020-04-07 20:48:06
Dissemination plan revised Websites, patent fillings, videos etc. 2020-04-07 20:48:06
Exploitation activity - yearly report 3 in knowledge subjected of protection Documents, reports 2020-04-07 20:48:06
Individualized press release for every partner Documents, reports 2020-04-07 20:48:05
Design of the logo, Launch of website, Twitter, Facebook, LinkedIn, Google Plus Documents, reports 2020-04-07 20:48:05
Plan and formal distribution of essential internal procedures and tools Documents, reports 2020-04-07 20:48:05
Exploitation activity - yearly report 1 in knowledge subjected of protection Documents, reports 2020-04-07 20:48:05

Take a look to the deliverables list in detail:  detailed list of FOLSMART deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Claudia Tallian, Alexandra Herrero-Rollett, Karina Stadler, Robert Vielnascher, Karin Wieland, Anna M. Weihs, Alessandro Pellis, Andreas H. Teuschl, Bernhard Lendl, Heinz Amenitsch, Georg M. Guebitz
Structural insights into pH-responsive drug release of self-assembling human serum albumin-silk fibroin nanocapsules
published pages: 176-187, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2018.10.002
European Journal of Pharmaceutics and Biopharmaceutics 133 2020-04-07
2018 Eugénia Nogueira, Marisa P. Sárria, Nuno G. Azoia, Egipto Antunes, Ana Loureiro, Diana Guimarães, Jennifer Noro, Alexandra Rollett, Georg Guebitz, Artur Cavaco-Paulo
Internalization of Methotrexate Conjugates by Folate Receptor-α
published pages: 6780-6786, ISSN: 0006-2960, DOI: 10.1021/acs.biochem.8b00607
Biochemistry 57/49 2020-04-07
2018 Nogueira, Eugénia Sofia Costa; Cavaco-Paulo, Artur
Folate-targeted liposomes for rheumatoid arthritis therapy
published pages: 43, ISSN: , DOI:
Abstract Book of the XII Spanish-Portuguese Conference on Controlled Drug Delivery - Tailoring drug delivery systems to the patients’ needs 2020-04-07
2018 Loureiro, Ana Isabel Sá; Cavaco-Paulo, Artur
Folic acid-tagged protein nanoemulsions with controllable size for cancer therapy
published pages: 105, ISSN: , DOI:
Abstract Book of the XII Spanish-Portuguese Conference on Controlled Drug Delivery - Tailoring drug delivery systems to the patients’ needs 2 2020-04-07
2018 Tallian, C., Herrero-Rollett, A., Stadler, K., Vielnascher, R., Wieland, K., Weihs, A. M., Teuschl, A. H., Lendl, B., Amenitsch, H, Guebitz, G. M.
Structural insights in modified HSA-SF nanocapsules for targeted drug delivery in rheumatoid arthritis therapy
published pages: 14, ISSN: , DOI:
Book of Abstracts of the 6th DocDay 2018 2020-04-07
2018 Anna Ohradanova-Repic, Eugénia Nogueira, Ingrid Hartl, Andreia C. Gomes, Ana Preto, Eva Steinhuber, Vanessa Mühlgrabner, Marko Repic, Mario Kuttke, Alexander Zwirzitz, Marek Prouza, Miloslav Suchanek, Gordana Wozniak-Knopp, Vaclav Horejsi, Gernot Schabbauer, Artur Cavaco-Paulo, Hannes Stockinger
Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells
published pages: 123-130, ISSN: 1549-9634, DOI: 10.1016/j.nano.2017.09.003
Nanomedicine: Nanotechnology, Biology and Medicine 14/1 2020-04-07
2018 Diana Guimarães, Eugénia Nogueira, Artur Cavaco-Paulo
Effect of sucrose in freeze-dried liposomes encapsulating drugs
published pages: 80, ISSN: , DOI:
Abstract Book of the XII Spanish-Portuguese Conference on Controlled Drug Delivery - Tailoring drug delivery systems to the patients’ needs 2020-04-07
2018 Elisabeth Dietersdorfer, Alexander Kirschner, Barbara Schrammel, Anna Ohradanova-Repic, Hannes Stockinger, Regina Sommer, Julia Walochnik, Sílvia Cervero-Aragó
Starved viable but non-culturable (VBNC) Legionella strains can infect and replicate in amoebae and human macrophages
published pages: 428-438, ISSN: 0043-1354, DOI: 10.1016/j.watres.2018.01.058
Water Research 141 2020-04-07
2018 Jennifer Noro, Rui L. Reis, Artur Cavaco-Paulo, Carla Silva
Ultrasound-assisted biosynthesis of novel methotrexate-conjugates
published pages: 51-56, ISSN: 1350-4177, DOI: 10.1016/j.ultsonch.2018.05.017
Ultrasonics Sonochemistry 48 2020-04-07
2018 Ana Loureiro, Jennifer Noro, Ana S. Abreu, Eugénia Nogueira, Diana Soares da Costa, Carla Silva, Artur Cavaco-Paulo
Absence of Albumin Improves in Vitro Cellular Uptake and Disruption of Poloxamer 407-Based Nanoparticles inside Cancer Cells
published pages: 527-535, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.7b00893
Molecular Pharmaceutics 15/2 2020-04-07
2018 Alexander Zwirzitz, Michael Reiter, Rostislav Skrabana, Anna Ohradanova-Repic, Otto Majdic, Marianna Gutekova, Ondrej Cehlar, Eva Petrovčíková, Eva Kutejova, Gerold Stanek, Hannes Stockinger, Vladimir Leksa
Lactoferrin is a natural inhibitor of plasminogen activation
published pages: 8600-8613, ISSN: 0021-9258, DOI: 10.1074/jbc.ra118.003145
Journal of Biological Chemistry 293/22 2020-04-07
2017 Johannes J. Kovarik, Elisabeth Kernbauer, Markus A. Hölzl, Johannes Hofer, Guido A. Gualdoni, Klaus G. Schmetterer, Fitore Miftari, Yury Sobanov, Anastasia Meshcheryakova, Diana Mechtcheriakova, Nadine Witzeneder, Georg Greiner, Anna Ohradanova-Repic, Petra Waidhofer-Söllner, Marcus D. Säemann, Thomas Decker, Gerhard J. Zlabinger
Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis
published pages: e0180900, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0180900
PLOS ONE 12/7 2020-04-07
2018 Anna Ohradanova-Repic, Christian Machacek, Celine Charvet, Franck Lager, Delphine Le Roux, René Platzer, Vladimir Leksa, Goran Mitulovic, Thomas R. Burkard, Gerhard J. Zlabinger, Michael B. Fischer, Vincent Feuillet, Gilles Renault, Stephan Blüml, Miroslav Benko, Miloslav Suchanek, Johannes B. Huppa, Takami Matsuyama, Artur Cavaco-Paulo, Georges Bismuth, Hannes Stockinger
Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.00852
Frontiers in Immunology 9 2020-04-07
2017 Verena Supper, Ingrid Hartl, Cyril Boulègue, Anna Ohradanova-Repic, Hannes Stockinger
Dynamic Interaction- and Phospho-Proteomics Reveal Lck as a Major Signaling Hub of CD147 in T Cells
published pages: 2468-2478, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1600355
The Journal of Immunology 198/6 2020-04-07
2017 C. Tallian
Development of protein-based stimuli responsive drug delivery systems
published pages: , ISSN: , DOI:
Functional biomaterials & enzymes symposium 2020-04-07
2017 C. Tallian, A. Herrero-Rollett, G. Tegl, D. Huber, L. Gutmann, R. Vielnascher and G.M. Guebitz
Release studies of stimuli-responsive modified HSA microcapsules for targeted drug delivery
published pages: , ISSN: , DOI:
BioNanoMed 2020-04-07
2017 Claudia Tallian, Karina Stadler, Lisa Gutmann, Alexandra Herrero-Rollett and Georg M. Guebitz
Development of protein-based targeted drug delivery systems
published pages: , ISSN: , DOI:
Designer Biology 2020-04-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FOLSMART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FOLSMART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.2.2.;H2020-EU.2.1.2.5.;H2020-EU.2.1.2.3.)

SKHINCAPS (2015)

SKin Healthcare by Innovative NanoCAPsuleS

Read More  

MOZART (2015)

MesopOrous matrices for localiZed pH-triggered releAse of theRapeuTic ions and drugs

Read More  

FOLSMART (2016)

Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis

Read More